Pfizer revenue misses estimates as top drugs disappoint | Reuters
Pfizer Inc (PFE.N), the largest U.S. drugmaker, reported quarterly revenue that missed estimates as sales of its key drugs fell short of expectations. Sales of breast cancer drug Ibrance, which is expected to face competition from rival Novartis AG’s (NOVN.S) Kisqali, rose more than 58 percent to $679 million, but missed the consensus estimate of $682 million, according to Barclays. “Key franchises came in well below expectations, […]